MOUNTAIN VIEW, Calif.,
April 21, 2015 /PRNewswire/
-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of
medication and supply management solutions to healthcare systems
and pharmacies, today announced that it has completed the
acquisition of MACH4 Pharma Systems, based in Bochum, Germany. MACH4's highly automated medication
management systems are installed in a base of over 1,000 retail and
hospital pharmacy customers primarily in Europe, with additional installations in
China and the Middle East.
MACH4 Pharma Systems' modular robotic solutions for dispensing
medications in original manufacturers' packages enables Omnicell to
serve the needs of a broad spectrum of pharmacy customers, from
large hospital systems to local retailers. The flexible design of
MACH4 systems provides both the chaotic method of storage and
retrieval that optimizes for high capacity storage in the minimum
amount of physical space, and the channel method of storage and
retrieval that optimizes for speed of delivery. MACH4 systems are
uniquely configurable to suit each specific customer's needs, and
complement unique capabilities of Omnicell dispensing systems to
handle medications in original manufacturers' packages.
The combination of Omnicell and MACH4 is intended to create a
comprehensive automated medication management offering for hospital
and retail pharmacies throughout Europe and emerging markets
internationally.
"The addition of MACH4 Pharma Systems is an important component
of Omnicell's international growth strategy," said Randall Lipps, chairman, president and CEO of
Omnicell. "We look forward to integrating MACH4's high-volume
medication management technology with Omnicell automated dispensing
systems in the markets we presently serve, while also expanding our
opportunities through MACH4's direct presence in Germany and France."
With the acquisition of MACH4, the expanded Omnicell portfolio
now includes innovative solutions that span robotic medication
management systems, automated dispensing cabinets and medication
adherence technology to meet the unique demands of the company's
growing base of customers worldwide to provide services across the
continuum of care.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new
efficiencies to improve patient care, anywhere it is delivered.
Omnicell is a leading supplier of comprehensive automation and
business analytics software for patient-centric medication and
supply management across the entire healthcare continuum— from the
acute care hospital setting to post-acute skilled nursing and
long-term care facilities to the home.
More than 3,000 customers worldwide have utilized Omnicell
Automation and Analytics solutions to increase operational
efficiency, reduce errors, deliver actionable intelligence and
improve patient safety. Omnicell Medication Adherence solutions,
including its MTS Medication Technologies brand, provide innovative
medication adherence packaging solutions to help reduce costly
hospital readmissions. In addition, these solutions enable
approximately 6,000 institutional and retail pharmacies worldwide
to maintain high accuracy and quality standards in medication
dispensing and administration while optimizing productivity and
controlling costs.
For more information about Omnicell, Inc. please visit
www.omnicell.com.
"Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements,
including, but not limited to, statements related to the closing of
the acquisition of MACH4 Pharma Systems and the benefits thereof,
including Omnicell's ability to utilize MACH4 Pharma Systems'
presence in Germany and
France, the combined company's
ability to deliver a comprehensive automated medication management
offering, its ability to meet the demands of its worldwide
customers and provide services across the continuum of care, and
other statements that are not historical facts. These
forward-looking statements are based on Omnicell's current
expectations and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, risks related to business combination
transactions, such as the risk that acquired business will not be
integrated successfully or that such integration may be more
difficult, time-consuming or costly than expected; risks related to
future opportunities and plans for the combined company, including
the reaction of the combined company's customers and potential
customers, the perceived complementary nature of the combined
company's products and solutions, uncertainty of the expected
financial performance, market opportunities and results of the
combined company following completion of the proposed acquisition;
and the possibility that if Omnicell does not achieve the perceived
benefits of the acquisition of MACH4 Pharma Systems as rapidly or
to the extent anticipated by financial analysts or investors, the
market price of Omnicell stock could decline; as well as other
risks related Omnicell's business, and those other risks detailed
from time to time under the caption "Risk Factors" and elsewhere in
Omnicell's SEC filings and reports, including in the Annual Report
on Form 10-K for the year ended December 31, 2014.
Omnicell undertakes no duty or obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events or changes in its
expectations.
OMCL - G
Logo -
http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omnicell-inc-closes-acquisition-of-germany-based-mach4-pharma-systems-300069484.html
SOURCE Omnicell, Inc.